2359 (2359) Fair Value & Analysis
Healthcare · Market cap HK$455B
Fair value as of: Jul 2, 2026
From 26 valuation models · updated today
Share price +17.8% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$73.13 – HK$153.70 · fair‑value band HK$93.00 – HK$301.13 · the HK$152.80 price screens above the HK$120.99 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
2359 (2359) currently trades at HK$152.80, while our model-based Fair Value estimate is HK$120.99 — implying the stock looks roughly 20.8% overvalued today. We read business quality at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, 2359 generated revenue of HK$46.2B at a net margin of 43.6%. Revenue grew 28.8% year over year. It earns a return on equity of 25.7%. The balance sheet holds a net cash position of HK$26.9B. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
2359 reported revenue of HK$45.5B in FY2025 versus HK$22.9B in FY2021, a compound +18.7%/yr. Reported net income was HK$19.2B in FY2025, compounding +39.2%/yr from FY2021.
Is 2359 fairly valued? → Check now
Recent news
- Complex Small Molecules Are Changing Drug R&D
- WuXi AppTec files complaint against U.S. DoD for linking it to Chinese military
- WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
- Clinical Trials Market Analysis/Forecasts 2026-2034 by Phases, Indications, Study Designs, Countries and Competitive Landscape
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $562.16 | $190.95 | -66% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $131.62 | $60.93 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 2359 (2359) undervalued?
What is the fair value of 2359?
What is the quality score of 2359?
What is the revenue of 2359 (2359)?
What is the net profit margin of 2359?
Does 2359 pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.